Literature DB >> 31478297

Proton pump inhibitors reduce breast cancer risk in gastric ulcer patients: A population-based cohort study.

Dah-Ching Ding1,2, Fung-Chang Sung3,4, Weishan Chen3, Jen-Hung Wang5, Shinn-Zong Lin6.   

Abstract

We aim to evaluate breast cancer risk relating to PPIs usage in women with peptic ulcer. From 2000 to 2013, incidence rates of breast cancer were compared between the two cohorts (with or without PPIs). Each study cohort consisted of 4838 women. The incidence density rate of breast cancer in the PPI cohort was 0.29 that in the comparison cohort (10.0 vs 31.6 per 10 000 person-years), with an adjusted HR (hazard ratio) of 0.32 (95% CI = 0.20-0.49) for the PPI cohort. In conclusion, the medication of PPIs is associated with reduced breast cancer risk for women with gastric ulcer.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  breast cancer; cohort study; gastric ulcer; proton pump inhibitors; retrospective

Mesh：

Substances：

Year:  2019        PMID： 31478297     DOI： 10.1111/tbj.13519

Source DB:  PubMed          Journal:  Breast J        ISSN： 1075-122X            Impact factor:   2.431


  9 in total

1.  Investigation of the effects of overexpression of jumping translocation breakpoint (JTB) protein in MCF7 cells for potential use as a biomarker in breast cancer.

Authors:  Madhuri Jayathirtha; Anca-Narcisa Neagu; Danielle Whitham; Shelby Alwine; Costel C Darie
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

Review 2.  The Interplay of Dysregulated pH and Electrolyte Imbalance in Cancer.

Authors:  Khalid O Alfarouk; Samrein B M Ahmed; Ahmed Ahmed; Robert L Elliott; Muntaser E Ibrahim; Heyam S Ali; Christian C Wales; Ibrahim Nourwali; Ahmed N Aljarbou; Adil H H Bashir; Sari T S Alhoufie; Saad Saeed Alqahtani; Rosa A Cardone; Stefano Fais; Salvador Harguindey; Stephan J Reshkin
Journal:  Cancers (Basel)       Date:  2020-04-07       Impact factor: 6.639

3.  Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome.

Authors:  Shiori Hiromoto; Takehiro Kawashiri; Natsumi Yamanaka; Daisuke Kobayashi; Keisuke Mine; Mizuki Inoue; Mayako Uchida; Takao Shimazoe
Journal:  Sci Rep       Date:  2021-04-26       Impact factor: 4.379

4.  Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells.

Authors:  Xiao Wang; Xu Xuetao; Mengshuo Wu; Panpan Wu; Zhaojun Sheng; Wenfeng Liu; Yan-Yan Ma; Den-Gao Zhao; Kun Zhang; Dongli Li; Xi Zheng; Susan Goodin
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

5.  Meaning and Significance of "Alkalization Therapy for Cancer".

Authors:  Hiromi Wada; Reo Hamaguchi; Ryoko Narui; Hiromasa Morikawa
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

Review 6.  Clinical review of alkalization therapy in cancer treatment.

Authors:  Reo Hamaguchi; Masahide Isowa; Ryoko Narui; Hiromasa Morikawa; Hiromi Wada
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

7.  Esomeprazole enhances the effect of ionizing radiation to improve tumor control.

Authors:  Kassidy A Hebert; Sergio Jaramillo; Wangjie Yu; Min Wang; Ratna Veeramachaneni; Vlad C Sandulache; Andrew G Sikora; Mark D Bonnen; Ananth V Annapragada; David Corry; Farrah Kheradmand; Raj K Pandita; Michelle S Ludwig; Tej K Pandita; Shixia Huang; Cristian Coarfa; Sandra L Grimm; Dimuthu Perera; George Miles; Yohannes T Ghebre
Journal:  Oncotarget       Date:  2021-07-06

Review 8.  A New and Integral Approach to the Etiopathogenesis and Treatment of Breast Cancer Based upon Its Hydrogen Ion Dynamics.

Authors:  Salvador Harguindey; Khalid Alfarouk; Julián Polo Orozco; Kevin Hardonniere; Daniel Stanciu; Stefano Fais; Jesús Devesa
Journal:  Int J Mol Sci       Date:  2020-02-07       Impact factor: 5.923

Review 9.  Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New H+-Centered Anticancer Paradigm of the Late Post-Warburg Era.

Authors:  Salvador Harguindey; Khalid Alfarouk; Julián Polo Orozco; Stefano Fais; Jesús Devesa
Journal:  Int J Mol Sci       Date:  2020-10-10       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.